Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H28N2O3.C4H4O4 |
| Molecular Weight | 508.5629 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C3=CC=C(O)C4=C3C=CC(=O)N4
InChI
InChIKey=IREJFXIHXRZFER-PCBAQXHCSA-N
InChI=1S/C24H28N2O3.C4H4O4/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24;5-3(6)1-2-4(7)8/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29);1-2H,(H,5,6)(H,7,8)/b;2-1-/t22-;/m0./s1
Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered as an aerosol formulation through a dry powder inhaler.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Gateways to clinical trials. | 2007 Jan-Feb |
|
| Gateways to clinical trials. | 2008 Oct |
|
| Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. | 2010 Dec |
|
| Indacaterol: in chronic obstructive pulmonary disease. | 2010 Dec 3 |
|
| [Indacaterol is a new once-daily beta2-agonist for treatment of COPD]. | 2010 Nov 22 |
|
| Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. | 2010 Oct 29 |
|
| An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. | 2012 Oct 1 |
|
| Metabolism and pharmacokinetics of indacaterol in humans. | 2012 Sep |
|
| Emerging Therapeutic Options for the Management of COPD. | 2013 |
|
| Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. | 2016 Oct |
|
| An update on LAMA/LABA combinations for COPD. | 2017 Jan |
|
| Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. | 2017 Jan 11 |
Sample Use Guides
The recommended dosage of Indacaterol is the once-daily inhalation of the contents of one 75 mcg Indacaterol capsule using the NEOHALER inhaler.
Route of Administration:
Respiratory
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
OSLIF BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
HIROBRIZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
ULUNAR BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
||
|
EMA ASSESSMENT REPORTS |
ONBREZ BREEZHALER (AUTHORIZED: PULMONARY DISEASE, CHRONIC OBSTRUCTIVE)
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1114325
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | RxNorm | ||
|
9827599
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | SWITZERF | ||
|
753498-25-8
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
M6240
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | Merck Index | ||
|
CHEMBL1095777
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
SUB30300
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY | |||
|
C81640
Created by
admin on Tue Mar 06 11:15:37 UTC 2018 , Edited by admin on Tue Mar 06 11:15:37 UTC 2018
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
